I recommend TTFields to all patients with newly diagnosed glioblastoma. I generally approach this during the second or third week of radiation treatment. I present TTFields as part of standard treatment for glioblastoma, similar to the discussion of adjuvant temozolomide.

Based on the long-term phase III randomized trial data on the use of TTF, which demonstrate a categorical survival benefit, we use a data-driven approach for all of our newly-diagnosed GBM patients. We recognize that considerable angst and controversy still exists regarding these data, but ther...

In our department, we utilize a multi-disciplinary approach. Surgeons, medical oncologists and radiation oncologists all play a role in recommending TTF in the adjuvant setting for newly diagnosed glioblastoma. Medical oncology nurses meet with the patients to provide chemotherapy education. During ...

Since the publication of EF-14 in 2017, I would say in my practice a fair amount of patients have already read about TTF in the adjuvant setting for glioblastoma. Generally, I’d discuss the data and current national guidelines regarding TTF such as NCCN. For patients who ar...

While we don't often address cost, I do think that should be discussed in this forum. This will only become more of an issue as we move towards alternative payment models which eventually could combine all oncology care.   The therapy costs about $20K per month. The Incremental Cost Effect...